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OBJECTIVE: To study the effects of mycophenolate sodium on mucociliary clearance.
INTRODUCTION: Mycophenolate is one of the most commonly used immunosuppressive drugs in lung
transplantation. Although its pharmacokinetic properties are well defined, its side effects on mucociliary clearance
have not yet been studied.
METHODS: Sixty rats were subjected to left bronchial section and anastomosis. The right bronchus was used as a
control. After surgery, the rats were assigned to two groups based on whether they received saline solution (n=30)
or mycophenolate sodium (n=30). After 7, 15, or 30 days of treatment, 10 animals from each group were sacrificed,
and in vitro mucus transportability, in situ mucociliary transport velocity and ciliary beat frequency were measured.
RESULTS: The analysis of mucus transportability revealed that neither mycophenolate nor bronchial section altered
any transportability related property for up to 30 days of treatment after surgery (p.0.05). With regard to ciliary
beat frequency, the operated left bronchi from the mycophenolate group showed a significant decrease on post-
surgical day 30 (p= 0.003). In addition, we found a significant reduction in the in situ mucociliary transport velocity
in the mycophenolate-treated group (p= 0.0001).
DISCUSSION: These data add important information regarding mucociliary clearance dysfunction following
mycophenolate therapy and suggest that mycophenolate might contribute to the high incidence of respiratory tract
infections in lung transplant patients. Further studies are needed to investigate the combined action of
mycophenolate with other immunosuppressive drugs and to establish methods to protect and recover mucociliary
clearance, an important airway defense mechanism.
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INTRODUCTION
Mycophenolate is currently one of the most commonly
used immunosuppressive drugs in lung transplantation
(LTx).1,2 Mycophenolate is a cell cycle inhibitor that
produces reversible noncompetitive blockade of the purine
synthesis pathway enzyme type II isoform of inosine
monophosphate dehydrogenase.3,4 Although its pharmaco-
kinetic properties are well defined, the side effects of
mycophenolate on respiratory epithelium, and mucociliary
clearance (MCC) in particular, have yet to be studied.
MCC is a first-line defense mechanism that protects the
lungs from the accumulation of particles and pathogens by
removing bacteria, viruses, antigens, and toxins that are
trapped in the mucus on the tracheobronchial airway
surface.5 An essential balance between mucus production
and its removal by ciliated cells is required for optimal
airway defense.6
Many studies have reported that MCC is impaired in lung
transplant patients.5 Several features that are unique to LTx
determine the predominance of fungal colonization and
infections in the early postoperative period. Perhaps one of
the most important factors is the direct communication
between the graft and the outside environment. In addition,
blood supply to the anastomosis is disrupted,7 causing chronic
mild ischemia and placing the graft at high risk for infection.8
In previous studies, we showed that cyclosporine,9,10
azathioprine,11 and bronchial section12 can all impair MCC
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by decreasing ciliary activity and mucus production and
secretion.
We hypothesize that mycophenolate can also play an
important role in impaired MCC in a bronchial section and
anastomosis rodent model. To test this hypothesis, we
analyzed the components of bronchial ciliated epithelium in
immunosuppressed rats by measuring ciliary beat fre-
quency (CBF), mucociliary transport velocity (MCTV), and
mucus transportability (MT).
MATERIALS AND METHODS
Experimental design
Sixty male Wistar rats weighting 300 g were subjected to
left bronchial section and anastomosis. The right bronchus
was used as an internal control. Following surgery, the rats
were assigned to two groups that received either saline
solution (Sal group, n = 30) or mycophenolate sodium
(MPS group, n = 30). The animals were maintained accord-
ing to the Guide for the Care and Use of Laboratory Animals,13
and our institution’s ethics committee approved the
protocol.
Surgical procedure
Anesthesia was induced with inhaled isoflurane
(Isoforine, Crista´lia, Itapira, SP, Brazil) in a closed
chamber, followed by orotracheal intubation with a
14-gauge catheter that was 6.5 cm in length. General
anesthesia was maintained by inhalation of 2% isoflurane
in pure oxygen via a nebulizer (Model 1223; Takaoka; Sa˜o
Paulo, SP, Brazil). Ventilation was achieved by a volume-
cycled ventilator (Harvard Apparatus, Holliston, MA,
USA) with a respiratory rate of 70 breaths/min and a
tidal volume of 10 ml/kg. A left thoracotomy was then
performed. The left main stem bronchus was dissected,
clamped, and completely transected, followed by an end-
to-end anastomosis with continuous running 8-0 poly-
propylene sutures. Finally, airflow was restored, and the
atelectasis of the left lung was resolved by hyperinflation.
Prior to closing the incision, a chest tube was inserted. The
chest tube and tracheal tube were removed immediately
after spontaneous respiration was restored. The surgical
procedure was performed with the aid of a stereomicro-
scope at 8x the original magnification.
Therapy
Following surgery, mycophenolate sodium (Myfortic,
180 mg, Novartis, Stein, Switzerland) was administered
to the animals via an orogastric tube at a daily dosage of
400 mg/m2/day diluted in saline. The animals in the Sal
group were subjected to the same therapeutic regimen
but received only the vehicle (saline) in an equivalent
volume.
Euthanasia
After 7, 15, or 30 days of treatment, ten animals from each
group were anesthetized with intraperitoneal sodium
pentobarbital (30 mg/kg) and sacrificed by exsanguination
by section of the abdominal aorta.14
Data collection
Immediately after the animals were sacrificed, their lungs
were removed en bloc from the thoracic cavity and placed in
a petri dish. After dissection, an incision was made in each
main bronchus, and mucus collection was performed by
inserting a small hair paintbrush into the lumen of each
bronchus. The mucus that adhered to the paintbrush was
then placed in a 0.6-ml microtube containing mineral oil (to
prevent dehydration) and stored at -70 C˚. MT was
measured using an in vitro frog palate model.15 The mucus,
which was previously defrosted at room temperature, was
placed on the frog palate ciliated epithelium, and its
movement was observed and timed with the aid of a
stereomicroscope equipped with a reticulated eyepiece. The
MT of the rat mucus was compared to that of the frog
mucus itself, and the results are therefore expressed as
relative velocity (rat/frog).
After collection of the mucus sample, the bronchi were
placed under a light microscope (Olympus, BX50, Tokyo,
Japan) connected to a video camera (Sony Trinitron, 3CCD,
Tokyo, Japan). A stroboscope (Machine Vision Strobe,
Cedarhurst, NY) was placed in front of the bronchi, and
CBF was measured by synchronization between cilia
movement and a stroboscope flashlight.
Finally, under the same microscope, in situ MCTV was
measured by direct observation of particles deposited on the
mucous layer moving across the bronchi. The movement of
the particles was timed, and the velocity was registered as
the distance covered over one minute.
Statistical analysis
All of the data were analyzed using the Statistic Package
for Social Sciences (SPSS version 13.0). An analysis of
variance was used to test the interference and interaction of
the factors. Comparisons between groups were performed
using the Bonferroni post-hoc test. The results are expressed
as mean¡SD, and the differences were considered sig-
nificance when p,0.05.
RESULTS
In the MT data collected from the rat mucus samples and
tested in the frog palate model, we found that neither
mycophenolate sodium (MPS) nor bronchial section altered
any transportability property for up to 30 days of treatment
after surgery (p.0.05; Figure 1).
With regard to the CBF measurements (Figure 2), the left
bronchi from MPS group showed a significant decrease on
postoperative day 30 (8.47¡1.12 Hz) compared to day 7
(10.72¡1.21 Hz, p,0.001) and day 15 (9.80¡1.16 Hz,
p = 0.026). In addition, a significant decrease was also
observed compared to the right bronchi from MPS group
at 30 days (9.73¡0.98 Hz, p= 0.003).
In situ MCTV (Figure 3) was significantly slower in the
MPS left group (0.021¡0.009 mm/min) than in the Sal left
group (0.038¡0.023 mm/min, p= 0.016) after 30 days. The
Sal left group showed an increase in MCTV compared
to 7 (0.018¡0.011 mm/min, p= 0.009) and 15 days (0.017¡
0.013 mm/min, p= 0.005) after the surgery and compared to
the Sal right group at 30 days (0.023¡0.018 mm/min,
p= 0.003). After 15 days of therapy, MCTV in the MPS
right group (0.038¡0.017 mm/min) was higher than in the
Sal right (0.018¡0.016 mm/min, p= 0.014) and MPS left
(0.019¡0.008 mm/min, p,0.001) groups. On postoperative
day 7, only the Sal left group showed MCTV impairment
(0.018¡0.011 mm/min) relative to the Sal right group
(0.028¡0.024 mm/min, p= 0.034).
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DISCUSSION
In the present study, we tested a drug that is commonly
used as part of the immunosuppressant triple therapy
regimen that consists of a corticosteroid (prednisone,
prednisolone, or methylprednisolone), a calcineurin inhibitor
(cyclosporine or tacrolimus), and an antimetabolite
(azathioprine or mycophenolate).1,2,16,17 We found that
mycophenolate impairs MCC in the operated bronchi of
animals treated for 30 days. Consistent with our previous
results,10,12 MCC was also impaired by bronchial section for
up to 15 days after surgery in saline-treated animals and
showed significant recovery by postoperative day 30. In the
immunosuppressed animals, however, this was not the case.
These data partially corroborate our initial hypothesis and
suggest that MPS might contribute to the high incidence of
infection in the respiratory tract of lung transplant patients.
Clinicians are continually searching for an adequate
immunosuppressive regimen in an attempt to maximize
efficacy against rejection while avoiding toxicity and
infection.17 Unfortunately, the choice of the immunosup-
pressive regimen for an individual patient’s requirements is
usually reactive rather than proactive.1 With respect to the
optimal early and maintenance immunosuppression regi-
mens, a recent review showed a strong contrast between the
wealth of evidence available in the renal transplant field and
the paucity, or at least a lack of consistency, of information
for LTx.19 Several factors could explain this problem,
including the small sample sizes and often contradictory
results of original studies of LTx and patients from a
heterogeneous group of pulmonary diseases who receive
lung transplants, which results in widely varying patient
phenotypes and individual pharmacogenomics.16
Based on these difficulties, the advantages of conducting
studies using animal models are clear. We believe that our
bronchial section rodent model is useful for clarifying
the adverse effects of immunosuppressive drugs on the
respiratory epithelium, specifically on mucociliary clearance.
We previously demonstrated that cyclosporine impaired
both ciliary beat frequency and mucus production/secretion
for up to 90 days of treatment.9,10 Conversely, azathioprine
caused a transiently perturbed on mucociliary transport on
postoperative days 7 and 15, and function was fully
recovered in the animals that were treated for 30 days.11
Together, these results reflect the controversy we find in the
literature regarding immunosuppression therapy for LTx,
even regarding drugs of the same class such as azathioprine
and mycophenolate, both of which are cell cycle inhibitors.
The use of mycophenolate (in place of azathioprine) has
increased since its commercialization and testing in renal and
Figure 1 -Mucociliary transportability (MT and rat/frog) of mucus samples obtained from the left (operated) or right (intact) bronchi of
rats treated with saline (Sal) or mycophenolate sodium (MPS) for 7, 15, or 30 days (p.0.05).
Figure 2 - Ciliary beatfrequency (CBF) of the left (operated) or right (intact) bronchi of rats treated with saline (Sal) or mycophenolate
sodium (MPS) for 7, 15, or 30 days. *The MPS left group showed the slowest frequency in 30 days (p,0.001 and p=0.026 vs. 7 and 15
days, respectively; p=0.003 vs. MPS right at 30 days).
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heart transplantation in the early 1990s. Some studies
suggest that mycophenolate may be more efficient than
azathioprine at preventing acute rejection in LTx, whereas
the single prospective, randomized study that compared
these two drugs did not find any benefit.18 Korom et al.2
concluded in their review that there is currently no
unambiguous evidence to support the superiority of myco-
phenolate over azathioprine in LTx that could justify its
wide-scale use as a first-choice antimetabolite.
Immunosuppression by mycophenolate occurs by virtue
of its active component mycophenolic acid (MPA) through
the inhibition of inosine monophosphate dehydrogenase
(IMPDH). T and B cells are more dependent on this
pathway than are other cells. Other potential mechanisms
of immunosuppression include inducing apoptosis in
activated T cells, decreasing the expression of adhesion
molecules (thereby decreasing the recruitment of inflam-
matory cells), and decreasing the production of inducible
nitric oxide and the resulting tissue damage.16
Mycophenolate has also been shown to inhibit the pro-
liferation of smooth muscle cells, fibroblasts, and endothe-
lial cells by blocking DNA synthesis in the S phase of the cell
cycle.20
To our knowledge, this is the first study to directly test the
effects of mycophenolate on the mucociliary apparatus.
Furthermore, we separately analyzed each of the two
principal components of this clearance mechanism, thereby
showing that only cilia movement from the left (sectioned)
bronchus was impaired after MPS therapy for 30 days. By
itself, this treatment did not alter the viscoelastic properties
of the mucus, at least in the frog palate model employed
here.
There are several techniques for monitoring MCC, the
most common of which is the use of insoluble particles that
can be directly observed, primarily in humans, through a
bronchoscope, by radiography or by external monitoring of
radiolabelled particles.21 In our rodent model, we used a
microscope equipped with a reticulated eyepiece, which
permitted the direct observation and timing of the progres-
sion of the particles trapped in the mucus layer across the
bronchus. Moreover, we developed a setup consisting of an
optic fiber connected to a stroboscope for analyzing CBF.10
A limiting point in this setup is its dependence on an expert
researcher to analyze and register CBF according to the
frequency of the stroboscopic flashlight. Finally, we used the
bullfrog palate, a well-established method for analyzing the
transportability of mucus samples.15 Because of its similar-
ity with mammalian respiratory epithelium, we could test
the transportability properties of the rat mucus samples in
comparison with the autologous (frog) mucus. We have
thus accumulated a considerable amount of information
regarding the physiological variability of mucociliary
clearance as a result of the effects of various immunosup-
pressant agents.9-11
Presently, we do not intend to analyze the intracellular
mechanisms of action of MPS in the cells of the mucociliary
system. We can, however, infer from our results that MPS
affects ciliated cells more than secretory (goblet) cells. This
is important for future studies that aim to avoid this
undesirable side-effect of mycophenolate therapy on MCC.
Presumably, the most informative method to study the
mechanism of MPS is to use cultured respiratory epithelial
cells. Given that we observed a reduction in CBF, we
propose including a well-known ciliary stimulant such as
extracellular adenosine triphosphate or acetylcholine22
when testing the effects of MPS.
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